title: In vitro activity of the new glycopeptide LY333328 against multiply resistant gram-positive clinical isolates.
abstract: The in vitro activity of LY333328 was compared with those of vancomycin and teicoplanin against 425 gram-positive clinical isolates, including a variety of multiply resistant strains. LY333328 at </=4 microgram/ml inhibited all microorganisms tested, including methicillin- and teicoplanin-resistant staphylococci, glycopeptide-resistant enterococci, penicillin- and multiply resistant pneumococci, and viridans and beta-hemolytic streptococci.
authors.affiliation: Servicio de Microbiología, Hospital General Universitario "Gregorio Marañón," Madrid, Spain. fgarrote@efd.net
authors.forename: F
authors.initials: F
authors.lastname: García-Garrote
authors.forename: E
authors.initials: E
authors.lastname: Cercenado
authors.forename: L
authors.initials: L
authors.lastname: Alcalá
authors.forename: E
authors.initials: E
authors.lastname: Bouza
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004352:Drug Resistance, Microbial; D018432:Drug Resistance, Multiple; D006020:Glycopeptides; D006094:Gram-Positive Bacteria / Q000187:drug effects*; D006801:Humans; D000077427:Lipoglycopeptides; D008826:Microbial Sensitivity Tests; D014640:Vancomycin / Q000031:analogs & derivatives
chemical_list: D000900:Anti-Bacterial Agents; D006020:Glycopeptides; D000077427:Lipoglycopeptides; C100708:oritavancin; D014640:Vancomycin